Fecal Microbiome Transplantation for Recurrent CDI: Treatment Efficacy and Safety with Oral Capsules
Journal of Gastrointestinal and Liver Diseases · 2025
DOI: 10.15403/jgld-5990 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2025. Verfasst von Tadas Urbonas und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas; Institute for Digestive Research, Lithuanian University of Health S…. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Clostridium Infections, Clostridioides difficile. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims: Fecal microbiota transplantation is an effective treatment method for recurrent Clostridioides difficile infection. Widely used enteric tube and colonoscopy methods demonstrate excellent efficacy and safety results. Recent data suggest that new fecal microbiota transplantation methods using oral capsules may provide a less invasive approach. In this study, we aimed to compare primary fecal microbiota transplantation efficacy as well as short- and long-term safety of two different administration routes: oral capsules and enteric tube.
Methods
This retrospective study included 60 consecutive patients who underwent fecal microbiota transplantation for recurrent Clostridioides difficile infection. Thirty participants received 50 oral capsules containing frozen material for a single day and 30 patients received fecal microbiota transplantation via nasoenteric tube. All patients received standard treatment with oral vancomycin 500 mg q.i.d. for at least five days before the procedure. After intervention, patients were followed up for at least six months. Data on Clostridioides difficile infection recurrences and health status were collected and analyzed.
Results
The oral capsules group consisted of 30 patients. Among them, 22 (73.3%) participants experienced resolution of symptoms after a single fecal microbiota transplantation, while eight (26.7%) patients developed recurrent diarrhea within eight weeks. The other 30 patients received treatment via nasoenteric tube. Among them, 24 (80%) patients were cured after a single fecal microbiota transplantation, while six (20%) experienced recurrent disease within eight weeks. The primary efficacy did not show significant differences between the two groups (p=0.85). Throughout the follow-up period, no serious adverse events or fecal microbiota transplantation related deaths were reported in both groups.
Conclusions
Fecal microbiota transplantation with frozen oral capsules is a safe, less invasive method with comparable efficacy to nasoenteric administration route.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas; Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania. tadas.urbonas@lsmu.lt.
- Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania. dalius.petrauskas@kaunoklinikos.lt.
- Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas; Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania. vytautas.kiudelis@lsmu.lt.
- Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas; Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania. laimas.jonaitis@lsmu.lt.
- Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania. jurgita.skieceviciene@lsmu.lt.
- Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas; Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania. rolandas.gedgaudas@lsmu.lt.
Zitieren
APA
Urbonas, T., Petrauskas, D., Kiudelis, V., Jonaitis, L., Skieceviciene, J., Gedgaudas, R., Kiudeliene, E., Valantiene, I., Zykus, R., Varkalaite, G., Inciuraite, R., Trapenske, E., Kulokiene, U., Jonaitis, P., Ramonaite, R., Velickiene, J., Zvirbliene, A., Morkunas, E., Kuliaviene, I., …, & Kupcinskas, J. (2025). Fecal Microbiome Transplantation for Recurrent CDI: Treatment Efficacy and Safety with Oral Capsules. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-5990
Vancouver
Urbonas T, Petrauskas D, Kiudelis V, Jonaitis L, Skieceviciene J, Gedgaudas R, et al. Fecal Microbiome Transplantation for Recurrent CDI: Treatment Efficacy and Safety with Oral Capsules. Journal of Gastrointestinal and Liver Diseases. 2025. doi:10.15403/jgld-5990
BibTeX
@article{Urbonas2025,
author = {Urbonas, Tadas and Petrauskas, Dalius and Kiudelis, Vytautas and Jonaitis, Laimas and Skieceviciene, Jurgita and Gedgaudas, Rolandas and Kiudeliene, Edita and Valantiene, Irena and Zykus, Romanas and Varkalaite, Greta and Inciuraite, Ruta and Trapenske, Elzbieta and Kulokiene, Ugne and Jonaitis, Paulius and Ramonaite, Rima and Velickiene, Justina and Zvirbliene, Aida and Morkunas, Egidijus and Kuliaviene, Irma and Sumskiene, Jolanta and Adamonis, Kestutis and Macas, Andrius and Kupcinskiene, Kristina and Lukosiene, Laura and Janciauskas, Dainius and Poskiene, Lina and Vitkauskiene, Astra and Ianiro, Gianluca and Gasbarrini, Antonio and Kiudelis, Gediminas and Kupcinskas, Juozas},
title = {Fecal Microbiome Transplantation for Recurrent CDI: Treatment Efficacy and Safety with Oral Capsules},
journal = {Journal of Gastrointestinal and Liver Diseases},
year = {2025},
doi = {10.15403/jgld-5990}
}
EUVIMED